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Abstract 
Cardiac dysfunction that develops during or after completion of cancer therapy is a growing 
health concern that should be addressed in a multidisciplinary setting. Cardio-oncology is a 
new discipline that focuses on screening, monitoring and treating cardiovascular disease 
during and after cancer treatment. A baseline cardiovascular risk assessment is essential. For 
high-risk patients, a tailored and detailed plan for cardiovascular management throughout 
treatment and beyond should also be established. Anthracycline and/or 
trastuzumab-containing chemotherapy and chest-directed radiation therapy are well known 
cardiotoxic cancer therapies. Monitoring for the development of subclinical cardiotoxicity is 
crucial for the prevention of clinical heart failure. Detecting a decreased left ventricular 
ejection fraction after cancer therapy might be a late finding; therefore, earlier markers of 
cardiac injury are being actively explored. Abnormal myocardial strain and increased serum 
cardiac biomarkers (eg, troponins and natriuretic peptides) are possible candidates for this 
purpose. An important method for preventing heart failure is the avoidance or minimization of 
the use of cardiotoxic therapies. Decisions must balance the antitumor efficacy of the 
treatment with its potential cardiotoxicity. If patients develop cardiac dysfunction or heart 
failure, they should be treated in accordance with established guidelines for heart failure. 
Cancer survivors who have been exposed to cardiotoxic cancer therapies are at high risk of 
developing heart failure. The management of cardiovascular risk factors and periodic 
screening with cardiac imaging and biomarkers should be considered in high-risk survivors. 
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Introduction 
Cardio-oncology is a new discipline that focuses on screening, monitoring and treating 
patients with heart disease during and after cancer treatment (1). It is a multidisciplinary field 
that requires oncologists and cardiologists to be brought together to provide short- and 
long-term cardiovascular (CV) care for cancer patients and survivors. Cardiac dysfunction 
and heart failure (HF) are well-recognized complications that impact the survival and quality 
of life in cancer patients. In this document, we discuss the different steps in 
cardio-oncological approach for CV monitoring and decision-making before, during and after 
cancer treatment with potential cardiac dysfunction.  
  
1. Baseline cardiovascular evaluation 
A baseline CV risk assessment is important prior to the initiation of cancer therapy. For 
high-risk patients, a tailored and detailed plan for CV management throughout treatment and 
beyond should also be established. The first step in the identification of higher risk patients 
for cardiotoxicity consists of a history and physical examination and a screening for CV risk 
factors. Unfavorable lifestyle choices (e.g., smoking, overweight, reduced physical activity) 
have been known to increase the risk of cardiotoxicity (2,3). Patients with pre-existing 
comorbidities (e.g., hypertension, diabetes, angina, HF) or previous histories of coronary 
bypass, stroke or thromboembolic events should receive particular attention during the course 
of anticancer therapy because their risk of developing adverse events due to cardiotoxicity is 
elevated (4). Blood hematochemical parameters should be measured together with blood 
pressure tests, electrocardiogram (ECG) and echocardiogram. Patients with poorly controlled 
hypertension, severe arrhythmias and left ventricular (LV) ejection fraction (LVEF) less than 
50% are at high risk for cancer therapy-induced cardiotoxicity (4). This assessment of the CV 
profile should then be taken into consideration by the oncologist in deciding the therapeutic 
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approach, in terms of drug selection and schedule, for each individual patient (Figure 1). 
Recently, the American Society of Clinical Oncology released a guideline for the prevention 
and monitoring of cardiac dysfunction in survivors of adult cancers (5). The guideline 
recommends that cancer patients who receive the following treatment should be considered at 
high risk for developing cardiac dysfunction (5):  
1) Treatment that includes any of the following:  
• High-dose anthracycline (e.g., cumulative doxorubicin dose ≥ 250 mg/m2, 
cumulative epirubicin dose ≥ 600 mg/m2) 
• High-dose radiotherapy (≥ 30 Gy) where the heart is in the treatment field 
• Lower-dose anthracycline in combination with lower-dose radiotherapy where the 
heart is in the treatment field 
2) Treatment with lower-dose anthracycline or trastuzumab alone and the presence of any 
of the following risk factors:  
• Multiple (≥ 2) CV risk factors, including smoking, hypertension, diabetes, 
dyslipidemia, and obesity, during or after completion of therapy 
• Older age (≥ 60 years) at cancer treatment 
• Compromised cardiac function (e.g., LVEF 50% to 55%, a history of myocardial 
infarction, ≥ moderate valvular heart disease) at any time before or during treatment 
3) Treatment with lower-dose anthracycline followed by trastuzumab. 
It should be noted that the target populations of this guideline are not Japanese cancer patients. 
Thus, careful consideration should be given to applying the guideline for Japanese patients.  
 
2. Cardiovascular monitoring during cancer treatment 
Left ventricular ejection fraction 
A drop in LVEF has been mostly used as a marker of cardiotoxicity. In many clinical studies, 
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cardiotoxicity was defined as a reduction in LVEF by more than 10 percentage points from 
baseline and < 50% (6,7). LVEF is one of the most important predictors of prognosis; patients 
with substantially reduced ejection fractions typically have a poorer prognosis (8).  
Echocardiography, nuclear imaging and magnetic resonance imaging (MRI) are 
used for the measurement of LVEF. Of these, 2-dimensional (2-D) echocardiography is the 
most commonly used imaging technique to monitor LVEF during and after chemotherapy. It 
is a widely available, reproducible, noninvasive modality that permits safe and serial 
assessment of cardiac function. However, intra- and inter-observer variability is a major 
limitation (9). In contrast, 3-D echocardiography has been shown to be the preferred 
technique for monitoring LVEF and is more reproducible in cancer patients (10). Nuclear 
imaging also can limit inter-observer variability in assessing LVEF, but it has the 
disadvantages of exposing patients to radiation and providing limited information on cardiac 
structure (11). The cardiac MRI might be useful for the noninvasive assessment of LV 
volumes and LVEF in the cancer setting. In addition to accurate and highly reproducible 
determination of LV volumes and systolic function, cardiac MRI is also useful for the 
detection of myocardial edema, perfusion abnormalities and fibrosis (2). However, because of 
the high cost and lack of availability, it is not routinely used.   
Although LVEF remains the most commonly accepted parameter of systolic 
function, it has shown low diagnostic sensitivity and low predictive power in detecting a 
subclinical myocardial injury (8). When a drop in LVEF is detected in cancer patients, they 
would have incurred irreversible myocyte damage by that stage (12). For this reason, earlier 
markers to detect subclinical cardiac toxicity have been in great demand.  
 
Myocardial strain 
An echocardiographic myocardial strain analysis using 2-D speckle tracking imaging is a 
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promising candidate for the detection of early cardiotoxicity. Global longitudinal strain (GLS) 
can be a useful early marker that is predictive of a further decrease in LVEF (13). The ideal 
cutoff value to define a clinically relevant change in strain values remains unclear. A 10% to 
15% early reduction in GLS during cancer therapy appears to be the most useful parameter 
for the prediction of cardiotoxicity (13). Thus, the myocardial strain seems to be a useful 
parameter for the early detection of cardiotoxicity. However, there are currently important 
limitations: its data analysis is time-consuming and depends on the quality of the acoustic 
windows, and different echo machines and software packages may yield different strain 
results, thereby making them difficult to compare (14).  
 
Serum markers 
Serum markers that detect damage of cardiomyocytes, such as troponin I or T, are useful in 
detecting acute cardiotoxicity (15). B-type natriuretic peptide (BNP), which is a cardiac 
neurohormone specifically secreted from the cardiac ventricles as a response to increased wall 
tension, may be used as a biomarker. However, there is still an insufficient amount of 
definitive evidence regarding a diagnostic or prognostic role in predicting 
chemotherapy-induced cardiomyopathy (8). 
 
3. Management of cardiotoxicity 
The primary goal is to prevent symptomatic HF and deliver optimal cancer therapy. The 
American College of Cardiology (ACC)/American Heart Association (AHA) identifies 4 
stages of HF. Stage A identifies patients who are at high risk for developing HF but have no 
structural heart change; stage B refers to patients with structural heart disease but who have 
never developed symptoms of HF; stage C denotes patients with past or current symptoms of 
HF associated with underlying structural heart disease; and stage D designates patients with 
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end-stage HF (16). HF is a progressive disease. That is, once a patient moves to a higher stage, 
regression to an earlier stage of HF is not observed (16). 
 
3.1. Primary prevention of heart failure  
Based on the above classification, every patient receiving cardiotoxic cancer therapy should 
be considered to be in stage A HF. Therefore, an important method for primary prevention 
involves the avoidance or minimization of the use of potentially cardiotoxic drugs if 
established alternatives exist (5). For patients with an indication of radiation therapy (RT), 
approaches to reduce cardiac radiation exposure using modern RT planning and delivery 
techniques can lower the risk of HF development (5). Decisions must balance the antitumor 
efficacy of the treatment with the potential for acute and long-term cardiotoxicity.  
 For patients planning to receive high-dose anthracyclines, co-administration of the 
cardioprotectant dexrazoxane or continuous infusion/liposomal formulation of doxorubicin 
may be an option to reduce the risk of cardiotoxicity, with low probability of compromising 
cancer-specific outcomes (5). However, there is no evidence to suggest that these approaches 
would reduce the risk of cardiotoxicity in patients receiving lower-dose anthracyclines.  
 Prophylactic use of angiotensin-converting enzyme (ACE) inhibitors, β-blockers, or 
angiotensin receptor blockers (ARBs) for prevention of chemotherapy-induced cardiotoxicity 
is an ongoing area of active investigation. On the basis of a recent meta-analysis, cardiac 
events (LV dysfunction and/or HF) were reduced with the prophylactic use of β-blockade 
(relative risk [RR]=0.31 [95% CI 0.16–0.63], p=0.001) or angiotensin antagonists (RR=0.11 
[95% CI 0.04–0.29], p <0.0001) when compared to controls (17). Overall, the evidence in 
support of primary prevention is quite limited because of a small sample size and variable 
follow-up and end points. The prophylactic use of these drugs might be an option for cancer 
patients at a high risk for cardiotoxicity. 
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The management of CV risk factors is thought to be also important for primary 
prevention (5). Although no randomized trials have demonstrated that aggressive 
management of CV risk factors resulted in improvements in long-term cardiac outcomes in 
cancer survivors, studies in non-cancer populations highlight the importance of vigilance and 
treatment of these modifiable risk factors (16).  
 
3.2. Treatment of asymptomatic cardiac dysfunction (stage B HF) 
If an asymptomatic LVEF reduction is detected, meeting the definition of stage B HF, patients 
should be treated in accordance with established guidelines (16). Drug therapy should include 
angiotensin antagonists (ACE inhibitors/ARBs) and β-blockers similar to the general HF (16). 
More specifically, patients with anthracycline-induced cardiotoxicity can have a better cardiac 
outcome when treated with ACE inhibitors and/or β-blockers early after the detection of 
cardiac dysfunction (6,18). Furthermore, the combination therapy may be more effective than 
either treatment alone (6,18). The time elapsed from the end of chemotherapy to the start of 
HF therapy can be a crucial variable for the recovery of cardiac function (18). However, there 
is currently no data to determine whether this HF therapy can be discontinued after 
achievement of complete recovery of LVEF, or should be prolonged throughout life. 
In the setting of cancer therapy-related cardiotoxicity, stage B HF could involve 
occult LV dysfunction (normal LVEF with abnormal myocardial strain and/or biomarkers) as 
well as overt LV dysfunction (decreased LVEF) (12). There is little evidence to guide the 
management of occult cardiotoxicity in stage B HF. Limited data have suggested a benefit 
from early initiation of ACE inhibitors (7) or β-blockers (19) in patients with troponin I 
elevation (7) or abnormal myocardial strain (19) without overt LVEF decline.  
No recommendations can be made regarding the continuation or discontinuation of 
cancer therapy in individuals with evidence of cardiac dysfunction (5). A multidisciplinary 
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discussion about the risks and benefits of further chemotherapy should be undertaken to 
determine subsequent treatment plans.  
 
3.3. Treatment of symptomatic heart failure (stage C and D HF) 
Traditionally, symptomatic HF due to cancer therapy has been believed to be resistant to HF 
treatment and was associated with a poor prognosis. A study published in 2000 showed that 
the 5-year survival rate of doxorubicin cardiomyopathy was below 45%, with a hazard ratio 
of 2.64 relative to idiopathic cardiomyopathy for death or cardiac transplantation over a 
follow-up of 4.4 years (20). However, recent data showed that in-hospital mortality did not 
differ among cancer patients with cardiotoxicity compared to other hospitalized HF patients 
(21). The majority of patients with cancer therapy-related cardiotoxicity received recent 
guideline-concordant therapies in the USA, including use of ACE inhibitors and β-blockers 
(21), which may be the reasons for the improvements in HF outcomes in these cancer 
patients. 
If patients develop symptomatic HF, they should be treated in accordance with 
established guidelines (16). ACE inhibitors/ARBs and β-blockers are key drugs for the 
treatment of symptomatic HF. Diuretics, aldosterone receptor antagonists and digoxin can be 
used based on the patient’s condition. Cardiac resynchronization therapy (CRT), also known 
as biventricular pacing, is a relatively new therapeutic approach in advanced HF patients with 
a reduced LVEF and intraventricular conduction delay (22). Ventricular dyssynchrony can 
impair ventricular pump function. CRT improves ventricular function by simultaneous pacing 
of both ventricles to improve electrical (and consequently mechanical) coordination and, 
therefore, pump efficiency. There have been only a few single-center, small observational 
studies examining CRT in cancer therapy-induced HF patients (23,24). In a larger study by 
Rickard et al. (24), 18 patients with anthracycline-induced cardiomyopathy who underwent 
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implantation of a CRT device were compared with 189 patients with other forms of 
non-ischemic cardiomyopathy. The authors showed significant improvements in LVEF and 
symptoms in anthracycline-induced cardiomyopathy patients with CRT. These changes were 
similar to patients in the non-ischemic cardiomyopathy cohort. Thus, CRT may hold promise 
for anthracycline-induced HF patients, but it is unclear whether the benefit of CRT can be 
extended to HF from nonanthracycline chemotherapeutic agents or to all forms of cancer 
therapy-induced HF. If patients develop stage D HF, patients should be evaluated to 
determine if the following treatments are available options: heart transplant, ventricular assist 
devices, continuous infusion of intravenous heart pump drugs, and end-of-life (palliative or 
hospice) care (12,16).  
 
4. Long-term CV monitoring and management in cancer survivors 
Long-term CV risk in cancer survivors 
Cancer survivors who have been exposed to cardiotoxic cancer therapies without developing 
overt cardiac dysfunction are considered to be in stage A HF. As the overall survival of 
patients with cancer continues to rise, more cancer survivors are faced with the risk of 
developing treatment-related cardiotoxicities. Cardiac disease has been found to be the 
leading cause of treatment-related nonneoplastic death among survivors of childhood cancer 
(25), breast cancer (26), and Hodgkin lymphoma (27). In a community-based, retrospective 
cohort study of 36,236 adult-onset cancer survivors (28), an increased risk of heart disease 
was found in patients diagnosed with breast, lung/bronchus, multiple myeloma, and 
non-Hodgkin lymphoma, when compared with non-cancer controls. Moreover, cancer 
survivors who developed CV disease had significantly worse all-cause mortality when 
compared with cancer survivors without CV disease (28). The increased CV risk may be 
driven by the shared risk factors for cancer and CV disease, the direct impact of cancer 
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therapy on the heart, an existing care gap in the cardiac care of patients with cancer and the 
increasing population of adult cancer survivors. It is important to take strategies to improve 
cardiovascular health in at-risk survivors long after completion of cancer therapy.   
 
Shared risk factors in cancer and CV disease 
Cancer and CV disease have similar risk factors, such as tobacco smoking, obesity, 
and diabetes mellitus (3). This may suggest shared biological mechanisms exist. Chronic 
systemic low-grade inflammation and oxidative stress are possibly involved in such 
mechanisms (3). These conditions increase the risk of coronary artery disease, 
cardiomyopathy, and cardiac sudden death in cancer survivors. In a relatively young survivor 
population in which modifiable cardiovascular risk factors were assessed, researchers 
observed that the presence of hypertension in particular increased the risk for severe cardiac 
events in a manner that was independent of the cancer therapy-related risk (29). This finding 
reinforces the need for careful screening of adult survivors for early detection of CV risk 
factors, and appropriate management may improve the cardiac outcome in cancer survivors.  
 
Long-term risk of chemotherapy-induced cardiotoxicity 
Most cardiotoxicity after anthracycline-containing therapy occurs within the first 
year (6). However, late-onset (>10 years) anthracycline-induced cardiotoxicity can potentially 
occur (30). Periodic screening with cardiac imaging and biomarkers, such as BNP, should be 
considered in survivors, particularly in those treated with high cumulative doses or who 
demonstrated reversible LV dysfunction during cancer treatment (11). Early discontinuation 
of cardioprotective HF therapy is not recommended (11). Anthracycline-related cardiotoxicity 
(cardiotoxicity type 1) is generally considered to be irreversible, while type 2 cardiotoxicity 
related to trastuzumab is frequently reversible. Cessation of HF treatment after normalization 
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of LVEF may be considered in patients with trastuzumab-induced cardiotoxicity (11).  
 
5. Conclusions 
Cardiac dysfunction developing during or after the completion of cancer therapy is a growing 
heath concern that should be addressed in a multidisciplinary setting. Many questions remain 
unanswered: how can we predict the development of cardiotoxicity, what is the best 
prevention strategy, how should we monitor those at risk of cardiac dysfunction, what are the 
best treatment strategies, and how long should HF treatment be continued in patients with 
stage B HF. There is an urgent need for collaborative research to address these questions.  
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Figure Legend 
Figure 1 Overview of the continuum of cardiovascular care on a timeline of cancer 
management.  
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, B-type 
natriuretic peptide; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure 
